Transactions
13
Insider / BICYCLE THERAPEUTICS PLC
Skynner Michael
CHIEF SCIENTIFIC OFFICER at BICYCLE THERAPEUTICS PLC
- Company
- BICYCLE THERAPEUTICS PLC
- Ticker
- BCYC
- First filing on record
- October 6, 2025
- Latest trade on record
- October 5, 2026
- SEC filings
- EDGAR ↗
Skynner Michael, CHIEF SCIENTIFIC OFFICER at BICYCLE THERAPEUTICS PLC, has disclosed 13 transactions in BCYC since October 6, 2025: 0 purchases (0 open-market buys) and 10 sales, worth about $88K at the reported prices. The latest was filed October 6, 2026, 1 day after the trade; 1 filing was late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
10
Avg. disclosure lag
2.8d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Skynner Michael made no purchases and 8 sales worth $72K, plus 3 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Skynner Michael has traded 1 stock on record; the largest by dollars is BCYC.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
1 of 6 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 10 | 15,353 | $88K |
| A | Grant or award | 3 | 210,000 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 11 | 0 | 8 · $72K |
| 2025 | 2 | 0 | 2 · $15K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| BCYC | Sell S | October 5, 2026 | October 6, 2026 | 1d | 503 | $4 | $1,796 | Form 4 ↗ | ||
| BCYC | Sell S | October 2, 2026 | October 6, 2026 | 4d | 1,942 | $3 | $6,739 | Form 4 ↗ | ||
| BCYC | Other A | July 15, 2026 | July 17, 2026 | 2d | 60,000 | — | — | derivative | Form 4 ↗ | |
| BCYC | Sell S | July 6, 2026 | July 7, 2026 | 1d | 532 | $4 | $2,293 | Form 4 ↗ | ||
| BCYC | Sell S | July 2, 2026 | July 7, 2026 | 5d | 1,859 | $4 | $7,938 | late | Form 4 ↗ | |
| BCYC | Sell S | April 6, 2026 | April 6, 2026 | 0d | 525 | $5 | $2,651 | Form 4 ↗ | ||
| BCYC | Sell S | April 2, 2026 | April 6, 2026 | 4d | 1,879 | $5 | $9,226 | Form 4 ↗ | ||
| BCYC | Other A | January 2, 2026 | January 6, 2026 | 4d | 100,000 | — | — | derivative | Form 4 ↗ | |
| BCYC | Sell S | January 5, 2026 | January 6, 2026 | 1d | 3,266 | $6 | $21K | Form 4 ↗ | ||
| BCYC | Sell S | January 2, 2026 | January 6, 2026 | 4d | 3,045 | $7 | $21K | Form 4 ↗ | ||
| BCYC | Other A | January 2, 2026 | January 6, 2026 | 4d | 50,000 | — | — | Form 4 ↗ | ||
| BCYC | Sell S | October 3, 2025 | October 6, 2025 | 3d | 978 | $8 | $8,225 | Form 4 ↗ | ||
| BCYC | Sell S | October 2, 2025 | October 6, 2025 | 4d | 824 | $8 | $6,922 | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| October 6, 2026 | Form 4 | 0001776582-26-000010 | 2 | published | EDGAR ↗ |
| July 17, 2026 | Form 4 | 0001776582-26-000008 | 1 | published | EDGAR ↗ |
| July 7, 2026 | Form 4 | 0001776582-26-000006 | 2 | published | EDGAR ↗ |
| April 6, 2026 | Form 4 | 0001776582-26-000004 | 2 | published | EDGAR ↗ |
| January 6, 2026 | Form 4 | 0001776582-26-000002 | 4 | published | EDGAR ↗ |
| October 6, 2025 | Form 4 | 0001776582-25-000004 | 2 | published | EDGAR ↗ |
Other insiders at BICYCLE THERAPEUTICS PLC
- GLAXOSMITHKLINE PLC Insider 33 rows
- Novartis Bioventures Ltd Insider 33 rows
- Thompson Travis Alvin Chief Financial Officer 14 rows
- Hannay Michael Charles Ferguson CHIEF PROD & SUPPLY CHAIN OFF 13 rows
- Lee Kevin CHIEF EXECUTIVE OFFICER 12 rows
- Gutierrez-Ramos Jose-Carlos SVP, Chief Science Officer 10 rows
- Perry Jennifer Scott Chief Operating Officer 10 rows
- Young Alethia Chief Financial Officer 7 rows
- Milnes Alistair CHIEF OPERATING OFFICER 6 rows
- BAKER BROS. ADVISORS LP Director 4 rows
Everyone on file, with contracts and lobbying under the company's name: BICYCLE THERAPEUTICS PLC.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 6 | 13 | October 6, 2025 | October 6, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.